Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Wolden · SciRah

Researcher profile · Semantic Scholar

M. Wolden

Share profile

M. Wolden — researcher profile on SciRah

h-index: 22
Works: 72
Citations: 2,208

Most-cited papers

Clinical Inertia in People With Type 2 Diabetes
K. Khunti, M. Wolden, B. L. Thorsted, M. Andersen +1 more
2013Diabetes Care427 citations Open access
Semantic Scholar
Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
K. Khunti, M. Davies, A. Majeed, B. L. Thorsted +2 more
2014Diabetes Care335 citations Open access
Semantic Scholar
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
S. Paul, K. Klein, B. L. Thorsted, M. Wolden +1 more
2015Cardiovascular Diabetology291 citations Open access
Semantic Scholar
A retrospective cohort study of more than 80,000 people
K. Khunti, M. Wolden, B. L. Thorsted, M. Andersen +1 more
2013180 citations
Semantic Scholar
A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function
M. Brod, M. Wolden, T. Christensen, D. Bushnell
2013Diabetes, obesity and metabolism71 citations Open access
Semantic Scholar
Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being
M. Brod, B. Pohlman, M. Wolden, T. Christensen
2012Quality of Life Research65 citations Open access
Semantic Scholar
Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization.
M. Brod, M. Wolden, T. Christensen, D. Bushnell
2013Value in Health59 citations Open access
Semantic Scholar
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
V. Aroda, M. Faurby, S. Lophaven, Josh Noone +2 more
2021Diabetes, obesity and metabolism54 citations Open access
Semantic Scholar
Cost‐effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin – from the UK health care cost perspective
M. Evans, M. Wolden, J. Gundgaard, B. Chubb +1 more
2014Diabetes, obesity and metabolism49 citations
Semantic Scholar
Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England
P. McEwan, Brian Larsen Thorsted, M. Wolden, J. Jacobsen +1 more
2015BMJ Open Diabetes Research & Care46 citations Open access
Semantic Scholar
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
J. Tibaldi, M. Hadley-Brown, A. Liebl, Steffen Haldrup +3 more
2019Diabetes, obesity and metabolism44 citations Open access
Semantic Scholar
Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK
M. Evans, M. Wolden, J. Gundgaard, B. Chubb +1 more
2015Journal of Medical Economics39 citations Open access
Semantic Scholar
A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
T. Siegmund, N. Tentolouris, S. Knudsen, A. Lapolla +4 more
2017Diabetes, obesity and metabolism38 citations Open access
Semantic Scholar
Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
R. Kolotkin, K. Fujioka, M. Wolden, J. Brett +1 more
2016Clinical Obesity37 citations Open access
Semantic Scholar
Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
Nick Freemantle, Luigi F. Meneghini, T. Christensen, M. Wolden +2 more
2013Diabetic Medicine37 citations Open access
Semantic Scholar
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
I. Lingvay, A. Kirk, S. Lophaven, M. Wolden +1 more
2021Diabetes Therapy35 citations Open access
Semantic Scholar
A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials
Nick Freemantle, M. Evans, T. Christensen, M. Wolden +1 more
2013Diabetes, obesity and metabolism34 citations Open access
Semantic Scholar
A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
Simon Heller, Chantal Mathieu, R. Kapur, M. Wolden +1 more
2015Diabetic Medicine30 citations Open access
Semantic Scholar
Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes
J. Yeaw, Won Chan Lee, M. Wolden, T. Christensen +1 more
2012Diabetes Therapy30 citations Open access
Semantic Scholar
The Association Between Body Mass Index and Health and Economic Outcomes in the United States
M. Dibonaventura, A. le Lay, Maya Kumar, M. Hammer +1 more
2015Journal of Occupational and Environmental Medicine28 citations
Semantic Scholar
Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417
K. Khunti, M. Wolden, B. L. Thorsted, M. Andersen +1 more
2014Diabetes Care24 citations Open access
Semantic Scholar
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
G. Fadini, M. Feher, T. K. Hansen, H. D. de Valk +4 more
2019Journal of Clinical Endocrinology and Metabolism23 citations Open access
Semantic Scholar
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes
S. Sreenan, M. Andersen, B. L. Thorsted, M. Wolden +1 more
2014Diabetes Therapy22 citations Open access
Semantic Scholar
Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom
Won Chan Lee, Elise Smith, B. Chubb, M. Wolden
2014Journal of Medical Economics21 citations Open access
Semantic Scholar
Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2
M. Brod, M. Wolden, D. Groleau, D. Bushnell
2014Journal of Medical Economics20 citations Open access
Semantic Scholar
The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.
X. Yue, Jiuhong Wu, Z. Ruan, M. Wolden +2 more
2020Value in Health Regional Issues17 citations Open access
Semantic Scholar
Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals
Katarina Steen Carlsson, K. Nilsson, M. Wolden, M. Faurby
2023BMC Cardiovascular Disorders16 citations Open access
Semantic Scholar
Diabetes management and daily functioning burden of non‐severe hypoglycemia in Japanese people treated with insulin
Y. Ohashi, M. Wolden, J. Hyllested-Winge, M. Brod
2017Journal of Diabetes Investigation15 citations Open access
Semantic Scholar
Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy
Steffen Haldrup, A. Lapolla, J. Gundgaard, M. Wolden
2020Journal of Medical Economics14 citations Open access
Semantic Scholar
Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
Katarina Steen Carlsson, M. Faurby, K. Nilsson, M. Wolden
2023Diabetes Therapy11 citations Open access
Semantic Scholar
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)
Søren T. Knudsen, A. Lapolla, B. Schultes, N. Tentolouris +3 more
2019Diabetic Medicine10 citations Open access
Semantic Scholar
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
H. Rodbard, B. Cariou, B. Zinman, Y. Handelsman +3 more
2014Diabetes, obesity and metabolism10 citations Open access
Semantic Scholar
Self-reported hypoglycaemia in patients with type 2 diabetes treated with insulin in the Hoorn Diabetes Care System Cohort, the Netherlands: a prospective cohort study
S. Rauh, F. Rutters, B. L. Thorsted, M. Wolden +6 more
2016BMJ Open9 citations Open access
Semantic Scholar
Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study
Cheli Melzer-Cohen, B. L. Thorsted, M. Wolden, G. Chodick +1 more
2017Diabetes Therapy8 citations Open access
Semantic Scholar
Economic burden of atherosclerotic cardiovascular disease: costs related to healthcare and loss of productivity; a matched case-control study in more than 450,000 Swedish individuals
K. Carlsson, K. Nilsson, M. Wolden, M. Faurby
2022European Heart Journal7 citations
Semantic Scholar
Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM)—A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)
J. Tibaldi, Steffen Haldrup, Viktor Sandberg, M. Wolden +1 more
2018Diabetes7 citations
Semantic Scholar
Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
C. Desouza, A. Kirk, K. K. Mangla, M. Wolden +1 more
2020BMJ Open Diabetes Research & Care6 citations Open access
Semantic Scholar
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
K. Kaku, M. Wolden, J. Hyllested-Winge, E. Nørtoft
2017Diabetes Therapy6 citations Open access
Semantic Scholar
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
J. Langer, M. Wolden, S. Shimoda, Miki Sato +1 more
2019Diabetes Therapy5 citations Open access
Semantic Scholar
Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial
J. Liutkus, K. Fujioka, A. Astrup, F. Greenway +9 more
20154 citations
Semantic Scholar
Cardiovascular events, mortality, early retirement and costs in >50 000 persons with chronic heart failure in Sweden
Katarina Steen Carlsson, M. Faurby, K. Nilsson, M. Wolden
2023ESC Heart Failure3 citations Open access
Semantic Scholar
Nationwide cardiovascular risk categorization: applying the European Society of Cardiology (ESC) guidelines to the Swedish National Diabetes Register.
B. Eliasson, J. Ekelund, Cecilia Nagorny Holmberg, M. Wolden +2 more
2022European Journal of Preventive Cardiology3 citations Open access
Semantic Scholar
954-P: GLP-1–Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)
Ildiko Lingvay, A. Kirk, S. Lophaven, M. Wolden +1 more
20203 citations
Semantic Scholar
Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
N. Tentolouris, S. Knudsen, A. Lapolla, M. Wolden +2 more
2019Advances in Therapy3 citations Open access
Semantic Scholar
Real Life Data Demonstrate Significant Reductions In HBA1C In T2DM Patients Switching From Other Insulins To Insulin Degludec
C. M. Cohen, B. L. Thorsted, M. Wolden, G. Chodick +1 more
20162 citations Open access
Semantic Scholar
Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom
B. Chubb, M. Evans, M. Wolden, T. Christensen +1 more
20132 citations Open access
Semantic Scholar
Health status in people with type 2 diabetes on basal-oral therapy is significantly improved with insulin degludec vs insulin glargine
J. Jendle, N. Freemantle, L. Meneghini, T. E. Christensen +2 more
20122 citations
Semantic Scholar
A Matrix to Determine Health Economic Viability Throughout Product Development: A Pharmaceutical Industry Perspective
M. Hemels, M. Wolden, T. R.
20092 citations
Semantic Scholar
A time trade-off study in the UK, Canada and the US to estimate utilities associated with the treatment of haemophilia
A. Okkels, C. Yssing, M. Wolden, M. N. Wahid
2024Health and Quality of Life Outcomes1 citations Open access
Semantic Scholar
Direct and indirect costs, early retirement, cardiovascular events and mortality in more than 50,000 adults with chronic heart failure in Sweden: a matched case-control study
K. Carlsson, M. Faurby, K. Nilsson, M. Wolden
2022European Heart Journal1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. L. Thorsted×9
Invite
B. L. Thorsted — researcher profile on SciRah
M. Faurby×6
Invite
M. Faurby — researcher profile on SciRah
M. Evans×6
Invite
M. Evans — researcher profile on SciRah
K. Khunti×5
Invite
K. Khunti — researcher profile on SciRah

×5

Invite

M. Brod — researcher profile on SciRah

Invite

K. Nilsson — researcher profile on SciRah

Invite

M. Andersen — researcher profile on SciRah

Invite

M. Davies — researcher profile on SciRah

T. Christensen×4

Invite

T. Christensen — researcher profile on SciRah

J. Gundgaard×4

Invite

J. Gundgaard — researcher profile on SciRah

Invite

B. Chubb — researcher profile on SciRah

Steffen Haldrup×4

Invite

Steffen Haldrup — researcher profile on SciRah